TGF-β1-Mediated PD-L1 Glycosylation Contributes to Immune Escape via c-Jun/STT3A Pathway in Nasopharyngeal Carcinoma

Xue-Min Ma¹, Yun-Fan Luo², Fang-Fang Zeng¹, Chang Su¹, Xiong Liu¹, Xiang-Ping Li¹* and Juan Lu¹*

¹ Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ² Department of Otolaryngology-Head and Neck Surgery, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China

Immunotherapy targeting programmed death ligand-1/programmed cell death protein-1 (PD-L1/PD-1) has achieved great success in multiple cancers, but only a small subset of patients showed clinical responses. Recent evidences have shown that post-translational modification of PD-L1 protein could regulate its protein stability and interaction with cognate receptor PD-1, thereby affecting anticancer immunotherapy in several solid tumors. However, the molecular mechanisms underlying how PD-1/PD-L1 expression is regulated still remain unclear in nasopharyngeal carcinoma (NPC). Here, we found N-glycosylation of PD-L1 in NPC cells and tissues. Mechanistically, we showed that STT3A transferred N-linked glycans to PD-L1, and TGF-β1 could positively regulate STT3A expression through activating c-Jun to bind to STT3A promoter. Functional assays showed that inhibition of TGF-β1 resulted in a decrease of glycosylated PD-L1 and enhanced cytotoxic T-cell function against NPC cells. Analysis of clinical specimens revealed that the expression of STT3A was positively correlated with TGF-β1 and c-Jun, and high STT3A expression was positively correlated with a more advanced clinical stage. Altogether, TGF-β1 activated c-Jun/STT3A signaling pathway to promote N-glycosylation of PD-L1, thus further facilitating immune evasion and reducing the efficacy of cancer immunotherapy. As such, all these data suggested that targeting TGF-β1 pathway might be a promising approach to enhance immune checkpoint blockade, and simultaneous blockade of PD-L1 and TGF-β1 pathways might elicit potent and superior antitumor activity relative to monotherapies.

Keywords: TGF-β1, PD-L1, glycosylation, nasopharyngeal carcinoma, immunotherapy

INTRODUCTION

Nasopharyngeal carcinoma (NPC) is a kind of epithelial squamous cell carcinoma that originates from the nasopharyngeal mucosa with a high incidence in South China and Southeast Asia. NPC is characterized by prevailing Epstein-Barr virus (EBV) infection and a heavy infiltration of immune cells in tumor microenvironment (1). At present, metastasis and recurrence are the main cause of...
death in NPC (1). Immunotherapy involving blocking programmed death ligand-1/programmed cell death protein-1 (PD-L1/PD-1) immune checkpoints has achieved great success in many solid tumors (2–6). Due to the efficacy of improving immunosuppressive microenvironment, anti-PD-1/PD-L1 treatment is suggested to be a promising therapeutic method for recurrent or metastatic NPC patients. Although PD-L1 is extremely highly expressed in NPC tissues (7), the response rate of PD-L1/PD-1 blocking therapy in NPC is only 20-30% (8–10). Moreover, an inconsistency occurs between the expression level of PD-L1 and the therapeutic effect (11). Therefore, a better understanding of the molecular mechanisms underlying how PD-1/PD-L1 expression is regulated will provide new insights to improve anti-PD-1/PD-L1 efficacy in NPC.

PD-L1, also known as CD274 or B7-H1, is a transmembrane glycoprotein expressed by tumor cells, macrophages and T cells. PD-L1 inhibits T cells activity and promotes immune evasion through binding to its receptor PD-1 on T cells (12). Recent studies have found that post-translational modifications (PTMs) of PD-L1 have played significant roles in modulating immunosuppression in cancers. PTMs of PD-L1, such as phosphorylation, N-glycosylation, acetylation and poly-ubiquitination, are known to emerge as important mechanisms in regulating its stability, translocation, and interactions with other proteins and directly affect PD-L1-mediated immune tolerance (13–15). A recent report indicated that glycosylation of PD-L1 led to the block of recognition of PD-L1/PD-1 by monoclonal antibodies and a low response rate of anti-PD-L1/PD-1 therapy in breast cancer (11).

TGF-β is a multifunctional cytokine with an important role in both physiologic and pathologic processes, including cancer. The aberrantly upregulated production of TGF-β has been strongly implicated in tumor progression, angiogenesis, and metastasis, as well as immune escape. TGF-β has been regarded as a critical immunosuppressive cytokine, which suppresses the antitumor activity of effector cells, including CD8+ T cells, natural killer (NK) cells, and macrophages (16). Several studies have indicated that TGF-β-mediated inhibitory immune microenvironment weakens the ability of PD-L1/PD-1 inhibitors to rebuild antitumor immune response, and ultimately leads to the resistance to PD-1/PD-L1 inhibitors (17–19). A recent report found that epithelial-mesenchymal transition (EMT) driven by TGF-β caused PD-L1 glycosylation by activating β-catenin to transcriptionally upregulate the expression of N-glycosyltransferase STT3, and eventually promoted immune escape in cancer stem cells (CSCs) (20). Furthermore, our previous study has revealed that enrichment of TGF-β1 in NPC microenvironment promotes immune escape by inducing chemotactic migration of Regulatory T (Treg) cells to remodel the inhibitory immune microenvironment via the TGF-β1-SMAD3-P13K- c-JUN-miR-200a-CXCL12-CXCR4 axis (21, 22). Based on these previous results, we wonder whether TGF-β1 exerts synergistic effects on the PD-L1 induction and attenuates tumor response to PD-L1 blockade in NPC.

In this study, we verified the N-glycosylation of PD-L1 in NPC and further investigated whether TGF-β1 induced glycosylation of PD-L1 to promote immune escape, which may contribute to develop more effective immunotherapy strategies and improve the survival rate of NPC patients.

**METHODS AND MATERIALS**

**Cell Culture**

All the NPC cell lines including 5-8F, CNE1, CNE2, SUNE1, HONE1, and HNE1 were obtained from the Cancer Research Center of Southern Medical University. Cells were cultured in RPMI 1640 medium (11875176, Gibco, USA) with supplement of 10% fetal bovine serum (2053264, BI, Israel), 100 mg/ml streptomycin and 100 U/ml penicillin (C12525, NCM Biotech, China) in an incubator at 5% CO2, 37°C. The PD-L1-knockdowned cells and c-Jun-overexpressed cells were cultured with antibiotic [puromycin (1μg/ml) (P8230, Solarbio, China)] while the Flag-PD-L1 cells and c-Jun- and STT3A-knockdowned cells were cultured with neomycin (400μg/ml) (G8160, Solarbio, China).

**Western Blotting**

The radio immunoprecipitation assay lysis buffer (RIPA) (P0013B, Beyotime, China) containing a protease-inhibitor cocktail (HY-K0010, MCE, USA) were used to extract proteins from cells. The proteins were lysed in SDS-loading buffer (FD006, Fdbio, China), then 20μg proteins were resolved on a 10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membrane (IPVH00010, Millipore, USA). The membrane was incubated with primary antibodies against PD-L1(13684, Cell Signaling Technology, USA), FLAG (PVDF, Cell Signaling Technology, USA), STT3A (12034-1-AP, Proteintech, USA), c-Jun (AF6089, Affinity, USA), HA (51064-2-AP, Proteintech, USA) and GAPDH (60004-1-Ig, Proteintech, USA) at a dilution of 1:1000, followed by incubation with species-specific (rabbit or mouse) HRP-conjugated secondary antibodies at a dilution of 1:5000. The immunoreactive bands were visualized by Omni ECL reagent (SQ101, EpiZyme, China).

**Protein Deglycosylation**

The protein lysate extracted from samples using RIPA was undergo glycoprotein denaturation at 100°C for 10min with 1 ml 10X GlycoBuffer, 2 ml neuraminidase and 3ul ddH2O. The extent of deglycosylation was assessed by mobility shifts on Western Blotting. The protein lysate exacted from samples using RIPA was undergo glycoprotein denaturation at 100°C for 10min with 1 ml 10X Glycoprotein Denaturing Buffer and ddH2O, and then incubated with PNGase F (P0704, NEB, USA) or O-glycosidase (P0733, NEB, USA) for 16h with 2μl 10X GlycoBuffer, 2μl 10% NP-40 and 5ul ddH2O or 2μl neuraminidase and 3ul ddH2O. The extent of deglycosylation was assessed by mobility shifts on SDS-PAGE gels.

**Generation of Stable Cells Using Lentiviral Infection**

The lentiviral–based short-hairpin RNA (shRNA) (Genechem, China) was used to knock down PD-L1, c-Jun and STT3A of 5-8F and CNE1 cells. Based on the knockdown of endogenous PD-L1, a pCMV-Flag-PD-L1 overexpressing plasmid was generated.
to reconstitute Flag-PD-L1. A pCMV-HA-c-Jun overexpressing plasmid was used to culture stable overexpressing c-Jun cell lines.

**RNA Extraction, Reverse Transcription and qRT-PCR**

Total RNA of cells was extracted RNA isolation Kit (RC112-01, Vazyme, China) and reversely transcribed to cDNA using a reverse transcription kit (R323-01, Vazyme, China). ChamQ SYBR RT-qPCR Master Mix (Low ROX Premixed) (Q331-02, Vazyme, China) was used to used make a 20µL reaction amplification system to perform reverse transcription quantitative polymerase chain reaction (RT-qPCR) on an ABI QuantStudio6 System. All samples were normalized to the internal control GAPDH mRNA, and the relative expression levels were calculated based on the $2^{-\Delta\Delta CT}$ method. The primer sequences for RT-qPCR are shown in **Supplementary Table 2**.

**ConA Lectin Binding Assay**

Immunoprecipitated PD-L1 proteins were subjected to SDS-PAGE gels, transferred onto PVDF (IPVH00010, Millipore, USA), blocked with RIPA buffer for 1h at room temperature, and then incubate by peroxidase-conjugated ConA lectin (dilute to 0.1 µg/ml with RIPA buffer) (L6397, Sigma-Aldrich, USA) for 2h. Wash the membrane with RIPA buffer and detection using a chemiluminescent substrate.

**Dual-Luciferase Assay**

For the preparation of the 293T cells for transfection, they (1 × 105 cells) were grown by incubation on a 24-well plate for 24 hours. The control pcDNA3.1 plasmid (4.0 µg/ml) or the c-Jun plasmid (4.0 µg/ml), together with the control vector, pGL3-basic (4.0 µg/ml) or the STT3A plasmid (4.0 µg ml) were added into the medium with Lipofectamine 2000 (116680119, Invitrogen, USA). Cell lysates were collected after 36h incubation and firefly/relinna luciferase values were measured by the Dual-Luciferase Reporter Assay System (E1910, Promega, USA).

**CHIP-PCR**

The EZ-Magna ChiP™ A/G (17-10086, Millipore, USA) was used to perform CHIP experiment according to the manufacturer’s instruction. Anti-c-Jun antibodies (AB40766, Abcam, USA) were used for immunoprecipitation and two primer sets (**Supplementary Table 3**) designed against human STT3A promoter were used to detect the bound DNA.

**Co-Culture Experiment**

Jurkat T cells were activated by Dynabeads Human T-Activator CD3/CD28(11161D, Gibco, USA), and were then co-cultured with 5-8F or CNE1 cells pretreated with SB431542 (20µM) (HY-431542, MCE, USA) or tunicamycin (15µg/ml) (T8480, Solarbio, China) for 48h at 3:1 (Jurkat: 5-8F/CNE1) ratio for 6h. The death rate of tumor cells was detected by CFSE/PI Double Stain Kit (BB4214, Bestbio, China). The medium supernatant of the co-culture system was collected for detecting the level of IL-2 by the ELISA kit (70-EK102, MultiSciences, China) according to manufacturer’s instructions.

---

**Clinical Samples and Immunohistochemistry**

The NPC tissue specimens (n=36) were collected from the Nanfang Hospital of Southern Medical University (Guangzhou, China). These tissue specimens were from biopsy samples of NPC patients (pathologically confirmed) in 2021. The TNM classification was performed according to the 8th edition of the UICC/AJCC staging criteria. The clinical characteristics of these 36 patients with NPC are shown in **Supplementary Table 3**. This study was approved by the Ethics Committee of Nanfang Hospital of Southern Medical University. Formalin-fixed, and paraffin-embedded tissues were sectioned at 4 mm thickness, then harvested and fixed in 4% paraformaldehyde overnight at 4° C. The antigen blocking was performed using 10% goat serum (SP-9000, Zsbo, China). The sections were probed overnight at 4°C with primary anti-TGF-β1 (PA5-40772, Invitrogen, USA), anti-c-Jun (AF6089, Affinity, USA) and anti-STT3A (sc-100796, Santa Cruz, USA) antibodies. DAB color reagent kit (ZLI-9018, Zsbo, China) was used for staining. The numbers of positive cells were measured by two independent pathologists through five randomly selected fields at ×400 magnification.

**Statistical Analysis**

The SPSS 20.0 software was used for statistical analyses. All data were from at least three independent experiments. The comparison between two independent groups of data following a normal distribution is analyzed by two-tailed student’s t-test. The relationship between STT3A and TGF-β1 or c-Jun was analyzed by the Spearman’s correlation analysis. The data are shown as the mean ± SEM unless otherwise. $p$-values of <0.05 were considered statistically significant.

**RESULTS**

**PD-L1 Was N-glycosylated in Nasopharyngeal Carcinoma**

We analyzed PD-L1 expression in human NPC tissues and six different NPC cell lines by western blot, and found that most of PD-L1 expression was presented as two kinds of molecular weight size, which were distributed at around 50kDa and ~40kDa respectively (**Figures 1A, B**). These findings were consistent with previous results in breast cancer (23), suggesting that the 50-kDa form in NPC might be glycosylated PD-L1, and the ~40-kDa form might be non-glycosylated PD-L1. To further confirm the glycosylation of PD-L1 in NPC, we treated 5-8F and CNE1 cells with recombinant glycosidase (peptide-N-glycosidase F; PNGase F) or O-glycosidase. Compared with O-glycosidase-treated groups, virtually all PD-L1 was un-glycosylated form. The ~40-kDa PD-L1 was un-glycosylated form and ~40-kDa PD-L1 was un-glycosylated form.
Inhibition of TGF-β1 by SB431542 Reduced PD-L1 Glycosylation In Vitro

To explore the relationship between TGF-β1 and PD-L1 glycosylation, SB431542, a TGF-β type I receptor inhibitor, was used to block the effect of TGF-β1 in 5-8F and CNE1 cells. The results showed that inhibition of TGF-β1 by SB431542 reduced PD-L1 expression (Figure 2A). Then, 5-8F and CNE1 cells stably overexpressing exogenous Flag-tagged-PD-L1 were constructed, in which the expression of PD-L1 was independently of the transcriptional regulation of endogenous PD-L1. If PD-L1 protein expression was upregulated or downregulated by any cytokines in those cells, it likely occurred through post-translational modifications. The results showed that the exogenous PD-L1 in Flag-PD-L1 5-8F and CNE1 cells could be reduced by SB431542 (Figure 2B). Moreover, PD-L1 lost its binding ability to ConA lectin after the treatment of SB431542 (Figure 2C). In summary, these results demonstrated that blocking the effect of TGF-β1 by SB431542 suppressed PD-L1 glycosylation in vitro.

SB431542 Downregulated Glycosylation of PD-L1 via C-Jun/STT3A Pathway In Vitro

Although SB431542 reduced PD-L1 glycosylation, the exact mechanism was still unclear. We verified that SB431542 also downregulated c-Jun expression in Flag-PD-L1 5-8F and CNE1 cells (Figure 2B). In our previous study, we also found that EBV-EBNA1 promoted the chemotraction of Treg cells by governing the protein-protein interactions of the SMAD3/c-JUN complex in a TGF-β1-dependent manner in NPC (21). Furthermore, we detected the expression of 15 glycosyltransferases related to PD-L1 glycosylation in 5-8F cells after the treatment of TGF-β1, and found that STT3A had the most significant increase in transcription levels (Figure S1). We assumed that SB431542 could downregulate PD-L1 glycosylation by blocking TGF-β1 receptor to inhibit c-Jun and STT3A. In order to explore the exact mechanism, we knocked down c-Jun expression in 5-8F and CNE1 cells with shRNA, and the results showed that silencing c-Jun inhibited STT3A expression and PD-L1 glycosylation (Figure 3A). Next, after knockdown of STT3A, glycosylated PD-L1 in 5-8F and CNE1 cells were also downregulated (Figure 3B). Furthermore, we overexpressed c-Jun and then knocked down STT3A in 5-8F and CNE1 cells. The data demonstrated that upregulation of PD-L1 glycosylation caused by c-Jun overexpression was reversed by knockdown of STT3A (Figure 3C). Altogether, these results demonstrated that SB431542 reduced PD-L1 glycosylation through c-Jun/STT3A pathway, and c-Jun was an upstream regulator of STT3A (Figure 3D).

C-Jun Was a Direct Transcriptional Regulator of STT3A

C-Jun is a major component of the dimeric transcription factor activator protein-1 (AP-1) (24), which regulates the expression of target genes at transcriptional level by binding to their promoters. Therefore, we speculated that c-Jun might regulate the expression of STT3A at the transcription level. We used UCSC and JASPAR databases to predict c-Jun-binding sites in the STT3A promoter (Figure 3E). A chromatin immunoprecipitation (CHIP) assay was performed to validate the interaction between c-Jun and
FIGURE 2 | Inhibition of TGF-β1 by SB431542 Reduced PD-L1 Glycosylation in Vitro. (A) Western blot analysis of PD-L1 in 5-8F and CNE1 cells treated by SB431542 with increasing concentrations. (B) Western blot analysis of PD-L1 and c-Jun in exogenous Flag-PD-L1 expressing 5-8F and CNE1 cells with the treatment of 20µM SB431542. (C) The glycosylation status of PD-L1 protein purified from SB431542 treating cells was analyzed by ConA lectin binding assay.

FIGURE 3 | SB431542 Downregulated Glycosylation of PD-L1 via C-Jun/STT3A Pathway in Vitro and C-Jun was a Direct Transcriptional Regulator of STT3A. (A) Western blot analysis of c-Jun, STT3A and PD-L1 after silencing c-Jun in 5-8F and CNE1 cells. (B) Western blot analysis of STT3A and PD-L1 after silencing STT3A in 5-8F and CNE1 cells. (C) Western blot analysis of c-Jun, STT3A and PD-L1 after overexpressing c-Jun without silencing STT3A in 5-8F and CNE1 cells. (D) Western blot analysis of PD-L1, c-Jun and STT3A in exogenous Flag-PD-L1 expressing 5-8F and CNE1 cells with the treatment of 20µM SB431542. (E) The binding motif of c-Jun from JASPAR database. (F) The CHIP-PCR assay was used to assess the binding of STT3A promoter region. (G) Anti-c-Jun-pulled down chromatin were analyzed by qRT-PCR. (H) A diagram showing the relationship of full-length and mutant STT3A promoters. (I) Dual-luciferase reporter gene assay was performed to indicate the interaction between c-Jun and STT3A. Bars, mean ± SD, *p<0.5, **p<0.01.
STT3A promoter. The data of CHIP-PCR showed that the predicted STT3A binding sequence was successfully pulled down by anti-c-Jun group (Figure 3F). And RT-qPCR analysis of the pulled down chromatin demonstrated that c-Jun could bind to STT3A promoter through the putative binding site in the anti-c-Jun group but not in the IgG group (Figure 3G). Then, we constructed a series of luciferase reporter vectors containing the full-length of the wild type (WT) or mutant (Mut) c-Jun promoter. The mutant STT3A promoters contained two degenerate c-Jun-binding elements, including Mut-1 (CTGACTGCCAT) and Mut-2 (GACTGTTGCTAT) (Figure 3H). Luciferase reporter assays displayed that c-Jun promoted the luciferase activity of STT3A promoter but not the control vector. Furthermore, Mut-1 and Mut-2 reduced the STT3A transactivation, indicating that Mut-1 and Mut-2 were the effective binding sites (Figure 3I). The above results revealed that c-Jun regulated the expression of STT3A at transcriptional level by binding to its promoter.

**STT3A Expression Was Positively Correlated With TGF-β1 and C-Jun in NPC Tissues, and High STT3A Expression Was Associated With a More Advanced Stage in NPC**

To further investigate the relationship among TGF-β1, c-Jun and STT3A in human NPC tissues, we analyzed the correlations among them in NPC tissues. As expected, STT3A expression was respectively positively correlated with TGF-β1 (r=0.412, p=0.013) and c-Jun (r=0.5859, p=0.0002) expression (Figures 4A–C). Meanwhile, the NPC patients with early-stage tumors (clinical stage I and II) had significantly downregulated expression of STT3A compared to those with a more advanced stage (clinical stage III and IV) (p<0.01) (Figure 4D), indicating that high STT3A expression was associated with a more advanced stage in NPC.

**Inhibition of TGF-β1 by SB431542 Increased T Cells Activity by Inhibiting PD-L1 Glycosylation In Vitro**

The above results have confirmed that TGF-β1 promoted PD-L1 glycosylation in NPC through c-Jun/STT3A pathway, and we wondered whether TGF-β1 induced immunosuppression by mediating PD-L1 glycosylation. A co-culture system containing NPC cells and Jurkat T cells was conducted to detect the effect of STT3A-knockdown, SB431542 and tunicamycin (TM) on T cells. The results showed that compared with control group, STT3A-knockdown group had greatly increased tumor cell death rate but lower than SB431542 or TM-treated groups (Figures 5A, B). We also detected IL-2 level in the supernatant of the co-culture system, and found that in SB431542 and TM pretreated groups, the secretion of IL-2 by T cells was highest, and IL-2 level of STT3A-knockdown group also had a significant increase compared with control group (Figures 5C, D).

![Figure 4](image-url) | STT3A Expression was Positively Correlated with TGF-β1 and C-Jun in NPC Tissues, and High STT3A Expression Was Associated with a more advanced stage in NPC. (A) Representative pictures of c-Jun and STT3A expression in NPC patients in TGF-β1-low and high expression groups. Scale bars represented 100 μm. (B, C) Pearson correlation analysis of the association between TGF-β1 and STT3A (r=0.412; p=0.013) and between c-Jun and STT3A (r=0.5859; p=0.0002) in NPC tissues. (D) Comparison of STT3A levels in 36 NPC patients with different clinical stages. **p<0.01.
The above results suggested that immunosuppression in NPC induced by inhibition of TGF-β1 was largely dependent on STT3A-regulated PD-L1 glycosylation.

**DISCUSSION**

Immunotherapy is one of the most encouraging treatment for cancer patients, and the most common immunotherapy strategy includes the interruption of the interaction between immune checkpoints expressed on tumor and immune cells, especially targeting PD-L1/PD-1 (25). PD-L1 is an important immunosuppressive contributor to trigger immune escape by binding to its receptor PD-1 (26). Recent evidence has shown that the expression status of PD-L1, as detected by immunohistochemistry (IHC) has exhibited a significant correlation with response to immunotherapy, and patients whose tumors overexpress PD-L1 by IHC have improved clinical outcomes with anti-PD-1-directed therapy (27). Emerging studies have reported that NPC tumor cells highly express PD-L1, with a positive expression rate from 89% to 100% (28), however, only 20%-30% of NPC patients respond well to anti-PD-L1/PD-1 therapy (8–10). Therefore, understanding the regulation of PD-L1 expression are urgently needed to further improve response to immunotherapy.

Increasing studies have revealed that the expression and function of PD-L1 are regulated by PTMs (29). Among them, N-glycosylation is important in PD-L1/PD-1-mediated tumor immunosuppressive function and influences the efficacy of immunotherapy (30). Li CW et al. reported that glycosylation on N192/200/219 of PD-L1 inhibited the degradation of itself through suppressing GSK3β-Trcp-induced PD-L1 polyubiquitination (23). Moreover, PD-L1 glycosylation promoted its interaction with PD-1 and further suppressed T cells activity in triple-negative breast cancer (TNBC) (31). In addition, many studies suggested that targeting glycosylation of PD-L1 was an effective strategy to improve anti-tumor activity. In breast cancer, STT3 upregulated PD-L1 via increasing PD-L1 glycosylation in CSCs. Etoposide, which could inhibit EMT-mediated STT3 expression, enhanced the therapeutic outcomes of T cell immunoglobulin mucin-3 (TIM-3) blockade therapy (20). It was later reported that targeting PD-L1 glycosylation by 2-deoxy-D-glucose (2-DG) combined with EGFR inhibitors reduced tumor size and enhanced anti-tumor immunity mediated by 4-1BB, a glycoprotein receptor belonging to the tumor necrosis factor receptor superfamily, in syngeneic mouse models of TNBC (32). However, it remains unknown whether glycosylation of PD-L1 contributes to immune escape in NPC.

In our study, we confirmed that PD-L1 was heavily glycosylated in NPC, and found that TGF-β1 played an important role in N-
glycosylation of PD-L1 by regulating glycotransferase STT3A in NPC. We also revealed that TGF-β1 could upregulate PD-L1 glycosylation and exert immunosuppressive effect via activating c-Jun/STT3A signaling pathway. Compared with the studies which reported that TGF-β1-induced EMT increased PD-L1 expression in NSCLC and TNBC, our data identified a novel pathway about TGF-β1-mediated PD-L1 glycosylation, further expanding the understanding of the regulatory mechanisms and cellular functions underlying PD-L1 glycosylation. Additionally, our data will also lead to the development of potentially effective therapeutics targeting PD-L1 glycosylation for clinical application.

As a driving factor of tumor progression, TGF-β can induce tumor cell plasticity by inhibiting the anti-tumor immune response, making epithelial tumor cells more mesenchymal, stem-like and resistant to immunotherapy. TGF-β also produces additional stromal modifiers that promote tumor progression and metastasis and shapes an immunosuppressive tumor microenvironment (16). Bintrafusp alfa is a dual-target inhibitor that can capture TGF-β while binding to PD-L1. This dual-target combination therapy can block the tumor-driving effect of TGF-β1 and overcome the immune escape induced by TGF-β1 (33), which provides more suitable conditions for the binding of monoclonal antibodies and PD-L1. It has been carried out in clinical trials of various tumors such as breast cancer, non-small cell lung cancer, prostate cancer, pancreatic cancer, bile duct cancer and cervical cancer and has achieved remarkable effects (34). In this study, we demonstrated that TGF-β1-mediated PD-L1 glycosylation promoted immune escape via c-Jun/STT3A pathway in NPC, which provided a theoretical basis for the clinical practice of bintrafusp alfa in NPC.

In summary, our study verified that TGF-β1 induced PD-L1 glycosylation and exerted immunosuppressive effect via c-Jun/STT3A signaling pathway in NPC. These results will provide a new understanding of the resistance mechanisms of anti-PD-1/ PD-L1 therapy in NPC, and suggest that targeting TGF-β1 pathway might be a promising approach to enhance immune checkpoint blockade in NPC.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Nanfang Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

X-PL and JL conceived the study and drafted the manuscript. X-MM, Y-FL, FZ, and CS performed the experiments. XL contributed to the quality. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by National Natural Science Foundation of China (81472535) and Natural Science Foundation of Guangdong Province, China (2019A1515010968).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.815437/full#supplementary-material

REFERENCES

1. Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal Carcinoma. Lancet (2019) 394(10192):64–80. doi: 10.1016/S0140-6736(19)30956-0
2. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nat Med (2002) 8(8):793–800. doi: 10.1038/nm730
3. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for Patients With PD-L1-Positive Advanced Gastric Cancer (KEYNOTE-012): A Multicentre, Open-Label, Phase 1b Trial. Lancet Oncol (2016) 17(6):717–26. doi: 10.1016/S1470-2045(16)00753-3
4. Szol M, Chen L. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clin Cancer Res (2013) 19(5):1021–34. doi: 10.1158/1078-0432.CCR-12-2063
5. Velchetti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Szol M, et al. Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer. Lab Invest (2014) 94(1):107–16. doi: 10.1038/labinvest.2013.130
6. Xu F, Jin T, Zhu Y, Dai C. Immune Checkpoint Therapy in Liver Cancer. J Exp Clin Cancer Res (2018) 37(1):110. doi: 10.1186/s13046-018-0777-4
7. Liu X, Shan C, Song Y, Du J. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Front Oncol (2019) 9:1111. doi: 10.3389/fonc.2019.01111
8. Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) Alone or in Combination With Gemcitabine Plus Cisplatin for Nasopharyngeal Carcinoma: Results From Two Single-Arm, Phase 1 Trials. Lancet Oncol (2018) 19(10):1338–50. doi: 10.1016/S1470-2045(18)30495-9
9. Hsu C, Lee S-H, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol (2017) 35(36):4050–6. doi: 10.1200/JCO.2017.73.3675
10. Ma BBY, Lim W-T, Goh B-C, Hui EP, Lo K-W, Pettinger A, et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol (2018) 36(14):1412–8. doi: 10.1200/JCO.2017.77.0388
11. Lee H-H, Wang Y-N, Xia W, Chen C-H, Rau K-M, Ye L, et al. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell (2019) 36(2):168–78. doi: 10.1016/j.ccell.2019.06.008
12. Han Y, Liu D, Li L. PD-1/PD-L1 Pathway: Current Researches in Cancer. Am J Cancer Res (2020) 10(3):727–42.
13. Dai X, Gao Y, Wei W. Post-Translational Regulations of PD-L1 and PD-1: Mechanisms and Opportunities for Combined Immunotherapy. Semin Cancer Biol (2021) 51044-579X(21):300103–6. doi: 10.1016/j.semcancer.2021.04.002

14. Hu X, Lin Z, Wang Z, Zhou Q. Emerging Role of PD-L1 Modification in Cancer Immunotherapy. Am J Cancer Res (2021) 11(8):3832–40. doi: 10.1016/j.yactm.2020.12.032

15. Hu X, Wang J, Chu M, Liu Y, Wang Z-W, Zhu X. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. Mol Ther (2021) 29(3):908–19. doi: 10.1016/j.molther.2020.12.032

16. Battle E, Massague J. Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity (2019) 50(4):924–40. doi: 10.1016/j.immuni.2019.03.024

17. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 165(1):35–44. doi: 10.1016/j.cell.2016.02.065

18. Mariahassan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. Tgfβ Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis. Nature (2018) 554(7693):538–43. doi: 10.1038/nature25492

19. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. Tgfβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature (2018) 554(7693):544–8. doi: 10.1038/nature25501

20. Hsu J-M, Chi M, Liu Y-J, Liu Y, Wang Z-W, Zhu X. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. Mol Ther (2021) 29(3):908–19. doi: 10.1016/j.molther.2020.12.032

21. Hsu J-M, Li C-W, Lai Y-J, Hung M-C. Posttranslational Modifications of PD-L1 by 2-Deoxyglucose Reverses PARP Inhibitor-Induced Immunosuppression in Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell (2018) 33(2):187–201. doi: 10.1016/j.ccell.2018.01.009

22. Shao B, Li C-W, Ling S-O, Sun L, Li Y-J, Hou J, et al. Glycosylation of PD-L1 by 2-Deoxyglucose Reverses PARP Inhibitor-Induced Immunosuppression in Triple-Negative Breast Cancer. Am J Cancer Res (2018) 8(9):1837–46.

23. Kim B-G, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel Therapies Emerging in Oncology to Target the TGF-β Pathway. J Hematol Oncol (2021) 14(1):55. doi: 10.1186/s13045-021-01053-x

24. Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL, et al. Dual Targeting of TGF-β and PD-L1 via a Bifunctional Anti-PD-L1/TGF-β Inhibitor-Induced Immunosuppression in Triple-Negative Breast Cancer. Am J Cancer Res (2021) 8(1):e00433. doi: 10.1165/jtc-2019-000433

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ma, Luo, Zeng, Su, Liu, and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction which does not comply with these terms.